<DOC>
	<DOCNO>NCT02000609</DOCNO>
	<brief_summary>The study aim compare pharmacodynamic effect ( cardiovascular effects- primary variable : Heart rate 4 hour post dosing- ) administration BDP formoterol administer CHF 1535 100/6 NEXThaler DPI CHF1535 pMDI two different dose level .</brief_summary>
	<brief_title>A Phase II , 5-way Cross-over Study Evaluate Pharmacodynamics `` Nexthaler '' Dry Powder Inhaler COPD Patients</brief_title>
	<detailed_description>The effect formulation serum potassium serum glucose general safety tolerability study treatment also evaluate</detailed_description>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>Male female adult ( ≥ 40 ≤ 75 year old ) . Outpatients diagnosis moderate/severe stable COPD , accord GOLD ( Global Initiative Chronic Obstructive Lung Disease ) guideline update 2013 least 6 month screen visit . A postbronchodilator FEV1 ( Forced Expiratory Volume one second ) ≥ 40 &lt; 80 % predict normal value FEV1/FVC ( Forced Vital Capacity ) &lt; 0.7 , 4 puff ( 4 x 100 µg ) salbutamol pMDI . If criterion meet screening , test repeat commence runin period . Ability use pMDI ( pressure metereddose inhaler ) DPI ( dry powder Inhaler ) device Current past smoker least 10 pack/years one packyear equivalent 20 cigarette per day 1 year Pregnant lactate female subject . Current diagnosis Asthma ( define current GINA ( Global Initiative Asthma guideline 2012 ( update ) , history allergic rhinitis . COPD exacerbation require systemic steroid /or antibiotic and/or oral nebulized beta 2agonists 4 week prior screen randomization . Lower Respiratory Tract Infection ( LRTI ) 4 week prior screen randomization . Patients serum potassium level &lt; 3.5 mEq/L ( milliequivalent per liter ) . History substance abuse drug abuse within 12 month prior screen visit . Known respiratory disorder COPD include limited α1 antitrypsin deficiency , active tuberculosis , bronchiectasis , sarcoidosis , lung fibrosis , pulmonary hypertension , restrictive lung disease interstitial lung disease . Intolerance contraindication treatment beta 2agonists and/or inhale corticosteroid allergy component study treatment . Patients treat noncardioselective βblockers month precede screen visit study period . Patients clinically significant cardiovascular disease accord investigator 's judgement . Thus include limited : congestive heart failure ( NYHA class &gt; 3 ) ; acute ischemic heart disease within past 12 month screen ; Sustained cardiac arrhythmia ( supraventricular ventricular , &gt; 30 second duration ) within 6 month screen ; Non sustain cardiac arrhythmia ( supraventricular ventricular , &gt; 3 beat &lt; 30 second end spontaneously asymptomatic ) ; History sustain nonsustained cardiac arrhythmia ( supraventricular ventricular ) ; 2nd 3rd degree Atrioventricular conduction block ; Left Bundle Branch Block . An abnormal 12lead ECG ( QRS &gt; 120 msec , PR &gt; 220 msec , HR &lt; 40 bpm , Heart Rate &gt; 110 bpm ) screen randomization . Patients whose electrocardiogram ( 12lead ECG ) show QTcF &gt; 450 m male QTcF &gt; 470 m female screen randomisation . Patients whose DBP/SBP high : DBP 90 mmHg SBP 160 mmHg screen randomization .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>pharmacodynamics COPD</keyword>
</DOC>